Drug development risk in HIV-1 clinical trials: The effect of drug class

Journal of Pharmaceutical Health Services Research

Volumn 2, Issue 4, 2011, Pages 211-216

  Osborne, Brendan J W ^a   Kaul, Rupert ^a   Parker, Jayson L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical trial; Drug approval; HIV; Pharmaceutical; Risk

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INTEGRASE INHIBITOR; INTEGRASE STRAND TRANSFER INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL (TOPIC); CLINICAL TRIAL RISK; CONTROLLED STUDY; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK; RISK MANAGEMENT;

EID: 84859860067     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/j.1759-8893.2011.00060.x     Document Type: Article

References (7)

1. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-873.
2. DiMasi JA etal. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 2010; 87: 272-277.
3. Kola I. The state of innovation in drug development. Clin Pharmacol Ther 2008; 83: 227-230.
4. Parker JL, Clare-Kohler J. The success rate of new drug development in clinical trials: Crohns disease. J Pharm Pharmaceut Sci 2010; 13: 191-197.
5. NIH Office of AIDS Research (OAR). NIH AIDS Research Budget [online]. Bethesda, MD: U.S. Department of Health and Human Services, 2009. (accessed 1 March 2010).
6. Panel on Antiretrovrial Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: U.S. Department of Health and Human Services. December 1, 2009; 1-161. (accessed 1 March 2010).
7. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3: 711-715.